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Abstract: 
Levo-tetrahydropalmatine (l-THP) is an alkaloid purified from the Chinese herbs 
Corydalis and Stephania and has been used in many traditional Chinese herbal 
preparations for its sedative, analgesic and hypnotic properties. Previous studies 
demonstrated that l-THP has antagonistic activity on dopamine receptors; thus, it may 
have potential therapeutic effects on drug abuse. However, whether l-THP affects 
ketamine-induced conditioned place preference (CPP) remains unclear. Therefore, the 
present study was designed to evaluate the effects of l-THP on the rewarding behavior 
of ketamine through CPP. Results revealed that ketamine (5, 10 and 15 mg/kg) 
induced CPP in rats. Furthermore, Ketamine (10 mg/kg) promoted the 
phosphorylation of extracellular-regulated kinase (ERK) and cAMP responsive 
element binding protein (CREB) in the hippocampus (Hip) and caudate putamen 
(CPu), but not in the prefrontal cortex (PFc). l-THP (20 mg/kg) co-administered with 
ketamine during conditioning inhibited the acquisition of ketamine-induced CPP in 
rats. Furthermore, l-THP (20 mg/kg) prevented the enhanced phosphorylation of ERK 
and CREB in CPu and Hip. These results suggest that l-THP has potential therapeutic 
effects on ketamine-induced CPP. The underlying molecular mechanism may be 
related to its inhibitory effect on ERK and CREB phosphorylation in Hip and CPu. 
The present data supports the potential use of l-THP for the treatment of ketamine 
addiction. 
Keywords: Levo-tetrahydropalmatine; ketamine; conditioned place preference; 
extracellular regulated protein kinase; cAMP responsive element binding protein 
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1. Introduction 
Ketamine is commonly used in surgery for its anesthetic, sedative, and analgesic 
properties [1]. Over the past decade, ketamine has emerged as a recreational drug [2], 
and the abuse of ketamine is increasing year by year. Long-term use of ketamine 
produced persistent changes in behavior and in brain structure associated with 
learning and memory [3]. Memories of the learned association between cues and the 
rewarding properties of abused drugs are difficult to extinguish and this contributes 
significantly to the high propensity to relapse [4]. Previous studies demonstrated that 
the mesolimbic dopamine system significantly affects drug-induced behavioral and 
neuronal changes [5]. The neural circuitry of drug-seeking behavior involves the 
prefrontal cortex (PFc), caudate putamen (CPu) and the nucleus accumbens (NAc) [6]. 
Ketamine can improve the release of dopamine in the NAc and activate dopamine D1 
receptors in the PFc by reducing glutamatergic inhibition of dopaminergic transmission 
and reducing dopaminergic re-uptake [7,8]. Ketamine is similar to other addictive 
drugs in terms of affecting behavior, such as locomotor sensitization [8,9], 
self-administration [10] and conditioned place preference (CPP) [11], which is a 
standard test of the rewarding/addictive properties of drugs [12,13]. Therefore, the 
dopaminergic system is increasingly recognized as a therapeutic target for drug 
addiction yet there is still no medication currently available for treating ketamine 
addiction in clinical practice. 
Tetrahydropalmatine (THP) is a major active ingredient of Corydalis ambigua and 
Stephania tetranada; it has sedative, neuroleptic, and analgesic effects [14]. 
Pharmacological research has revealed that l-THP is an antagonist of dopamine D1 and 
D2 receptors; l-THP is more closely associated with dopamine D1 receptors than with 
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D2 receptors [15]. l-THP also affects dopamine D3 receptors [16,17]. These profiles of 
l-THP suggest that it may have potential therapeutic effects on drug addiction [18]. 
l-THP can attenuate methamphetamine-induced locomotor sensitization [19], CPP 
[20], oxycodone-induced CPP [21], and cocaine self-administration [17]. However, the 
effect of l-THP on the rewarding behavior of ketamine in rats and its underlying 
molecular mechanisms remains unclear. 
ERK is a kinase that plays important roles in second messenger signaling 
pathways and is implicated in playing a role in the development of addiction to various 
drugs, including cocaine and methamphetamine. The phosphorylation of ERK is 
enhanced by addictive drugs [22,23], and this process is related to 
methamphetamine-induced rewarding behavior [24]. Furthermore, the inhibition of 
ERK phosphorylation attenuates cocaine-induced CPP [25]. CREB regulates gene 
expression in cell signaling pathways [26] and is also closely related to drug addiction. 
Morphine enhances CREB phosphorylation in the hippocampus (Hip) of mice 
exhibiting CPP [27]. Thus, ERK and CREB phosphorylation may be significantly 
related to drug-abuse properties. Nevertheless, studies have yet to clarify the 
mechanism by which l-THP modulates the development of ketamine-induced CPP and 
the relevance of the activation of ERK and CREB phosphorylation in the brain of rats. 
In the present study, a CPP model was used to determine the effects of l-THP on 
the rewarding behavior of ketamine. The relationship between rewarding behaviors and 
changes in ERK and CREB phosphorylation in CPu, Hip and PFc in Sprague-Dawley 
(SD) rats was investigated. 
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2. Materials & Methods 
2.1. Animals  
Male SD rats (200-220 g) were purchased from the Academy of Military Medical 
Sciences (AMMS, China). All the animals were maintained on 12 h/12 h light/dark 
cycle at 22 ± 2 oC and 55 ± 5% humidity with food and water ad libitum, and were 
acclimatized for 1 week. The rats were handled daily for 1 week to adapt to the 
situation before treatment. All experimental procedures involving animals were 
approved by the Institutional Animal Care and Use Committee of Shanxi Medical 
University and accordance with the guidelines of National Institute of Health (NIH) 
guideline (NIH publication NO. 8023. Revised 1978). 
 
2.2. Reagents 
l-THP (99.00%) was purchased from the Sigma-Aldrich Inc. (USA) and it was 
dissolved in distilled water. Ketamine hydrochloride was obtained from Hengrui 
pharmaceutical factory (Jiang Xi, RP China). Rabbit anti-P-ERK antibody and rabbit 
anti-ERK antibody were acquired from Cell Signaling Technology (USA). Goat 
anti-rabbit IgG antibody was purchased from Boster Company (Wuhan, RP China). 
Rabbit anti-CREB and rabbit anti-P-CREB antibody were procured from Abcam 
(Cambridge, UK). The volume of intraperitoneal (i.p.) injection was 10.0 ml/kg. 
 
2.3. Experimental design 
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2.3.1. Ketamine addiction experiment.  
In this experiment, different doses of ketamine were administered to reveal the 
rewarding effect of ketamine. The rats were divided into four groups randomly (n = 7 
per group) consisting of (i) a control group treated with saline alone; (ii) a group 
treated with ketamine of 5 mg/kg; (iii) a group treated with ketamine of 10mg/kg; (iv) 
a group treated with ketamine of 15 mg/kg. 
 
2.3.2 l-THP therapeutic experiment.  
In this experiment, the dose of ketamine was 10 mg/kg; different doses of l-THP 
were treated in combination to study the therapeutic effect of l-THP. The rats were 
divided into four groups randomly (n = 6 per group) consisting of (a) a control group 
treated with saline alone; (b) a group treated with ketamine of 10 mg/kg; (c) a group 
treated with ketamine of 10 mg/kg in combination with l-THP of 10 mg/kg; (d) a 
group treated with ketamine of 10 mg/kg in combination with l-THP of 20 mg/kg. 
l-THP was administered 30 min before ketamine was administered. 
 
2.4. CPP apparatus 
The CPP apparatus (JLBeHv, China) consists of two equal-sized compartments (L 
* W * H: 30 cm * 30 cm * 40 cm) with a 7 cm * 10 cm sliding door in the center of the 
base. One compartment had 2 cm wide black and white horizontal stripes and a 
wire-mesh floor, whereas the other compartment had 2 cm wide black and white 
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vertical stripes and a bar metal grid rod floor [28]. The time that the rats spent in each 
compartment were recorded by infrared monitoring system. 
 
2.5. Conditioned place preference procedure 
The ketamine-induced CPP was examined by a three-phase CPP procedure 
similar to that described before [29,30] with modifications (Fig.1A). Briefly, the 
experiment consisted of pre-test phase (1 day); conditioning training phase (10 days), 
and post-test phase (1 day). For pre-test phase (the 1th day), each rat was drug free 
and was placed in the compartment randomly with free access to the entire CPP 
apparatus for 15 min. The time of rat spent in each compartment was recorded. The 
rat who spends over 600 s of the 15 min in either compartment were excluded from 
further analysis (10% of all animals). For conditioning training phase (from the 2th 
day to the 11th day), ketamine was paired with the non-preferred side (horizontal 
stripes compartment). On the 2th day, Group (i) received an i.p. saline injection and 
was confined in the vertical stripes compartment for 40 min; meanwhile, Groups 
(ii)-(iv) received different doses of ketamine (5 mg/kg, 10 mg/kg, and 15 mg/kg) 
injection (i.p.) respectively and they were confined in the horizontal stripes 
compartment for 40 min. All the groups received an i.p. saline injection and were 
confined in the vertical stripes compartment for 40min on the 3th day. Groups (ii)-(iv) 
received ketamine and saline injections alternatively in two consecutive days which 
was referred to as a conditioning session, while Group (i) received i.p. saline in both 
compartments. All the groups experienced a total of five conditioning sessions from 
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the 2th to 11th day. During the post-test phase (the 12th day), all the rats were allowed 
to explore the two compartments freely for 15 min without injections. The time the 
rats spent on the drug-paired side (horizontally striped box) was recorded.  
To study the effect of l-THP on the acquisition of ketamine-induced CPP, l-THP 
was administered 30 min before ketamine injections during the conditioning phase 
(the 2th, 4th, 6th, 8th, 10th day) respectively. 
 
2.6. Sample preparation 
All rats were sacrificed on the 12th day after the behavior test was completed. The 
whole brain was collected rapidly. The Hip, PFc and the CPu were dissected and stored 
at −80 oC for Western blot analysis. 
 
2.7. Western blot  
Western blot assay was performed using standard protocols. The samples were 
homogenized in ice-cold RIPA lysis buffer (Beyotime Institute of Biotechnology, 
Shanghai, China) containing phenyl-methylsulfonyl fluoride (PMSF). Homogenates 
were incubated in an ice bath for 3 h and then centrifuged at 12,000 rpm for 20 min at 4 
oC. The protein concentration of the samples then was quantified by Bradford BCA 
protein assay. After tissue lysate was mixed in loading buffer and boiled for 5 min, 
equal amounts of denatured total protein were loaded and separated through 12 % 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The proteins were 
transferred to 0.45 μm polyvinylidene difluoride (PVDF) membranes. The membranes 
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were blocked with 5% BSA in tris-buffered saline for 2 h at 4 oC and then incubated 
with primary antibodies, namely, anti-p-CREB (1:5000), anti-p-ERK (1:2000), 
anti-CREB (1:750), and anti-ERK (1:1000) at 4 oC overnight. The membranes were 
incubated with the corresponding secondary antibodies at 4 oC for 2 h. Bands were 
visualized by using the enhanced chemiluminescence kit according to the 
manufacturer’s instruction. Western blots were scanned and analyzed by Alpha View 
SA Image software. 
 
2.8. Data analysis and statistical analysis 
The place preference score was defined as the time spent in the drug-paired 
chamber during the post-test session minus the time spent in the drug-paired chamber 
during the pre-test session [31]. 
SPSS version 16.0 statistical software (SPSS, Inc., Chicago, Il, USA) was used 
for statistical analysis. One-way ANOVA with post-hoc multiple comparisons 
(Bonferroni test) was performed to analyze multi-group. Data are presented as mean ± 




3.1. Ketamine-induced place preference 
As shown in Fig. 1B, the saline-control rats exhibited no preference for either the 
drug- or saline-associated compartment. The mean CPP score was 25.7 ± 9.7 sec. 
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Ketamine (5-15 mg/kg, i.p.) produced place preference (F (3, 24) =5.986, *p < 0.05). 
The mean conditioning scores were 104.3 ± 3.5 sec (5 mg/kg, *p < 0.05), 132.3 ± 4.6 
sec (10 mg/kg, * p < 0.05) and 153.1 ± 16.6 sec (15 mg/kg, * p < 0.05). N = 7 per 
group. 
 
3.2. Effects of l-THP on the acquisition of ketamine-induced place preference 
As shown in Fig. 1C, Ketamine (10 mg/kg, i.p.) produced a significant 
preference for the drug-associated place. The mean conditioning scores was 137.8 ± 
6.2 sec. However, the effect was inhibited by pretreatment with l-THP (20 mg/kg): the 
mean conditioning scores was 38.2 ± 8.8 sec (F (3, 20) =8.665, #p < 0.05). While, 
l-THP (10 mg/kg) did not significantly affect the development of ketamine-induced 
CPP: the mean conditioning scores was 118 ± 9.7 sec (p > 0.05). N = 6 per group. 
 
3.3. Effect of l-THP on ERK and CREB phosphorylation in Hip from conditioned place 
preference rats 
As shown in Fig. 2A, ketamine (10 mg/kg) had significant effects on the level of 
p-ERK in the Hip (*p < 0.05 vs. saline group) in rats. The level of p-ERK in l-THP 
(10 mg/kg) pre-treatment group was slight lower than ketamine group, but there was 
no significance (p > 0.05). However, ketamine-induced activation of p-ERK was 
significantly reversed by pre-treatment with l-THP (20 mg/kg) in the conditioning 
phase (F (3, 20) =5.150, #p < 0.05 vs. ketamine group). N = 6 per group. 
l-THP prevents ketamine drug activity 
 11 
As shown in Fig. 2B, the level of p-CREB (in the Hip) in alone ketamine group 
significantly increased (*p < 0.05), compared with saline group. l-THP (10 mg/kg) 
pre-treatment could not significantly reverse p-CREB in Hip (p > 0.05). However, 
l-THP (20 mg/kg) pre-treatment significantly inhibited the increase of p-CREB’s level 
in Hip (F (3, 8) =17.90, #p < 0.05, compared with ketamine group). N = 3 per group. 
 
3.4. Effect of l-THP on ERK and CREB phosphorylation in CPu from conditioned place 
preference rats 
Compared with saline, ketamine significantly increased the level of p-ERK in the 
CPu (*p < 0.05). Multiple comparisons revealed that the ketamine-induced activation 
of p-ERK was significantly prevented by the pre-treatment of l-THP (10 and 20 mg/kg) 
in the conditioning phase (F (3, 16) =10.42, #p < 0.05, compared with ketamine group). 
N = 3 per group. These results were shown in Fig. 3A.  
The level of p-CREB was significantly increased in the CPu of the rats in the 
ketamine group (*p < 0.05 compared with the saline group). l-THP pre-treatment (20 
mg/kg) significantly reversed the increase (F (3, 8) =5.299, #p < 0.05, compared with 
the ketamine group). These results were shown in Fig. 3B. N = 3 per group. 
 
3.5. Effect of l-THP on ERK and CREB phosphorylation in PFc from conditioned place 
preference rats 
  We attempted to find out whether ketamine or l-THP increased the level of CREB 
Ser133 phosphorylation in PFc from conditioned place preference rats. The results 
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demonstrated that ketamine or l-THP did not alter the level of ERK phosphorylation in 
PFc from conditioned place preference rats (F (3, 8) =0.4647, p > 0.05). These results 
were shown in Fig. 4A. N = 3 per group. 
  As shown in Fig. 4B, neither ketamine nor l-THP could significantly activate 
p-CREB in PFc (F (3, 8) =0.3657, p > 0.05). N = 3 per group. 
 
4. Discussion 
In our study we show for the first time that the drug l-THP, a DA receptor 
antagonist that also affects adrenergic and serotonergic receptors [32,33] inhibits the 
acquisition of ketamine-induced conditioned place preference (CPP) by regulating the 
expression of ERK and CREB phosphorylation in the brain of rats. Previous studies 
demonstrate that l-THP can attenuate methamphetamine-induced CPP [20], 
oxycodone-induced CPP [21], cocaine self-administration [17], and heroin 
self-administration [34], but no data has been published previously that demonstrates 
that l-THP may also have effects on the rewarding behavior of ketamine. In the 
present study, ketamine (5, 10 and 15 mg/kg, i. p.) induced CPP in the rats. This 
conclusion is consistent with that described in previous studies [35-37]. Besides, we 
found that l-THP (1.25, 2.5, 5.0, 10.0, 20.0 mg/kg, i.p.) alone did not produce 
conditioned place preference [20]. However, l-THP inhibited the acquisition of 
conditioned place preference induced by ketamine. These results suggest that l-THP 
may be useful for the treatment of ketamine addiction. 
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The conditioned place preference paradigm has been widely used as a model for 
studying the rewarding effect of drugs with addictive properties. The actual learning 
process in this task can be manifold, including classical conditioning but also operant 
conditioning [13]. Hence, one has to exercise caution when assigning specific learning 
mechanisms and brain areas to the drug effects in the interpretation of the experiments. 
Many drugs, such as amphetamine, cocaine and opioids can induce CCP [38]. In the 
present study, we found that ketamine induced CCP in rats. It has been previously 
shown that ketamine has rewarding effects with addictive properties [39]. Ketamine is 
a N-methyl-D-aspartate (NMDA) receptor antagonist, and previous studies 
demonstrated that NMDA receptor antagonists can induce rewarding behavior [35-37]. 
The drug activates the mesolimbic dopamine reward system by reducing the 
glutamatergic inhibition on dopaminergic transmission. For instance, several 
neurochemical studies have revealed that ketamine increases dopamine release in the 
nucleus accumbens [40]. In addition, NMDA receptor antagonists can increase 
extracellular dopamine levels by inhibiting dopamine reuptake [35,39].  
The mechanism by which l-THP inhibits the rewarding effects of ketamine is most 
likely by blocking dopaminergic receptors in the nucleus accumbens. Dopaminergic 
transmission drives the reward system, and activation of dopamine receptors is related 
to cocaine-induced CPP [22]. Moreover, the microinjection of dopamine receptor 
antagonists into relevant brain regions attenuates the development of addictive 
behaviors [41]. The pharmacological properties of l-THP include the antagonism of 
dopamine D1 and D2 receptors and the actions at D3 receptors [18]. Therefore, l-THP 
l-THP prevents ketamine drug activity 
 14 
may have potential effects on the treatment of drug abuse. Reports showed that l-THP 
can attenuate methamphetamine-induced CPP [20], oxycodone-induced CPP [21], 
cocaine self-administration [17], and heroin self-administration [34]. In our study, 
l-THP was pretreated 30 min before ketamine injection to investigate the effects of 
l-THP on adjusting ketamine-induced CPP. We found that l-THP (20 mg/kg) could 
significantly inhibit ketamine-induced CPP in the rat. l-THP attenuated the 
development of ketamine-induced CPP possibly because they bind to dopamine D1 and 
D2 receptors and block activation. These results indicate that the inhibiting effect of 
l-THP is due to its antagonistic activity on the dopaminergic system. 
Some of the underlying molecular mechanisms based on long-term behavioral 
changes caused by addictive drugs have been investigated in the present study. The 
activation of the ERK and CREB pathway in relevant brain regions can induce the 
development of addictive behaviors. For example, METH- and cocaine-induced CPP 
occurred when ERK and CREB were activated in distinct brain regions [24]. The 
pre-injection of the MAPK antagonist abolished the development of cocaine-induced 
CPP [25]. The activation of ERK induces the direct or indirect phosphorylation of 
various transcription factors, including CREB, which is essential for long-term 
behavioral and synaptic changes. Previous studies demonstrated that dopamine D1 
receptors are essential for cocaine-induced phosphorylation of ERK in specific brain 
regions and drug-induced ERK activation can be inhibited by associated dopamine D1 
antagonists or D1 receptor mutation [25]. Therefore, although the exact mechanisms 
remain unclear, these findings indicate that l-THP, as a dopamine receptor antagonist, 
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may inhibit dopamine receptors in associated brain regions and decrease the level of 
ERK and CREB phosphorylation, which contribute to the inhibition of 
ketamine-induced CPP in rats. We therefore analyzed the levels of ERK and CREB 
phosphorylation in the Hip, PFc and CPu. There was a significant increase in levels of 
p-ERK and p-CREB in the ketamine-treated group. Furthermore, l-THP (20 mg/kg) 
pretreatment partially inhibited the increase of p-ERK and p-CREB levels in Hip and 
CPu. The inhibition of l-THP in ketamine-induced CPP performance was consistent 
with the reduced levels of p-ERK and p-CREB protein levels. The role of l-THP on 
ketamine-induced molecular changes indicated that the inhibition of ERK and CREB 
phosphorylation in relevant brain regions may be related to the treatment effects of 
l-THP on ketamine-induced rewarding behavior in rats. 
Specific dopamine receptor antagonists may be used to alleviate drug addiction 
because of the effect on the mesolimbic dopamine system in modulating drug abuse 
[42]. However, dopamine receptor antagonists cannot be used widely because they may 
potentially reinforce addiction and promote drug abuse [43]. Unlike other dopamine 
receptor antagonists, l-THP derived from traditional Chinese medicine has been used 
safely for years without inducing side effects, including reinforcing addiction or 
promoting drug abuse [18]. These results demonstrate that l-THP does not impair basic 
hedonic processes, but rather, specifically inhibits the rewarding efficacy of drugs of 
abuse. Therefore, l-THP could be a potential candidate for the treatment of drug 
addiction. 
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5. Conclusion 
This study confirmed that l-THP can modulate the development of 
ketamine-induced CPP. Moreover, the inhibition of ERK and CREB phosphorylation 
in the Hip and CPu may be involved in the effects of l-THP on the modulation of 
ketamine-induced CPP. Therefore, l-THP may be a potential drug treatment for 
ketamine addiction. However, the precise mechanisms and safe use of l-THP for 
humans should be further investigated.  
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Fig. 1 (A) The conditioned place preference (CPP) behavioral schedule. K: ketamine, 
S: saline. (B) Effect of different doses of ketamine on place conditioning. Data are 
expressed as mean ± SEM. (n = 7 per group). * p < 0.05 compared with the saline group; 
(C) Effect of pretreatment with l-THP (10, 20 mg/kg, i.p.) on the place conditioning 
produced by ketamine (10 mg/kg, i.p.) in rats. Rats were pretreated with l-THP 30 min 
prior to each ketamine injection. Data are expressed as mean ± SEM. (n = 6 per group). 
* p < 0.05 vs. saline group, # p < 0.05 vs. the ketamine group. 
 
Fig. 2 (A) Effect of l-THP on p-ERK in the Hip from conditioned place preference rats; 
(B) Effect of l-THP on p-CREB in the Hip from conditioned place preference rats. 
Values are expressed as mean ± SEM, * p < 0.05 vs. saline group, # p < 0.05 vs. the 
ketamine group. 
 
Fig. 3 (A) Effect of l-THP on p-ERK in the CPu from conditioned place preference rats; 
(B) Effect of l-THP on p-CREB in the CPu from conditioned place preference rats. 
Values are expressed as mean ± SEM. * p < 0.05, compared with the saline group, # p < 
0.05, compared with the ketamine group. 
 
Fig. 4 (A) Effect of l-THP on p-ERK in PFc from conditioned place preference rats; (B) 
Effect of l-THP on p-CREB in PFc from conditioned place preference rats. Values are 
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expressed as mean ± SEM. * p < 0.05, compared with the saline group, # p < 0.05, 
compared with the ketamine group. 
 
